RDY · Dr Reddys Laboratories Ltd
$11.76
+0.03 (+0.26%)
At close · Jul 29
Market Cap
$9.80B
Shares
833.00M
Dr Reddys Laboratories Ltd Earnings Call Transcripts
Every quarterly earnings call for Dr Reddys Laboratories Ltd (RDY) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Earnings call
FY26 · Q2
2025-09-30
Dr Reddys Laboratories Ltd Q2 FY2026 Earnings Call
Positive tone
Biosimilars pipeline (rituximab, abatacept, tocilizumab)
Margins and cost optimization
GLP-1 / peptides opportunity
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2025-06-30
Dr Reddys Laboratories Ltd Q1 FY2026 Earnings Call
Positive tone
Semaglutide opportunity
R&D and innovation investment
Biosimilars and complex pipeline
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2025-03-31
Dr Reddys Laboratories Ltd Q4 FY2025 Earnings Call
Confident tone
Gross margin pressure
R&D and pipeline investment
Revenue and EBITDA growth
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2024-12-31
Dr Reddys Laboratories Ltd Q3 FY2025 Earnings Call
Positive tone
Semaglutide and GLP-1 opportunity
Biosimilars pipeline
North America generics
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2024-09-30
Dr Reddys Laboratories Ltd Q2 FY2025 Earnings Call
Confident tone
R&D and pipeline
Russia and CIS business
Margins and cost structure
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2024-06-30
Dr Reddys Laboratories Ltd Q1 FY2025 Earnings Call
Confident tone
India branded generics market
SG&A cost pressure and margins
Consumer healthcare business build-out
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2024-03-31
Dr Reddys Laboratories Ltd Q4 FY2024 Earnings Call
Positive tone
R&D Investment
Biosimilars Pipeline
PSAI Segment
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q2
2023-09-30
Dr Reddys Laboratories Ltd Q2 FY2024 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2023-06-30
Dr Reddys Laboratories Ltd Q1 FY2024 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-03-31
Dr Reddys Laboratories Ltd Q4 FY2023 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2022-12-31
Dr Reddys Laboratories Ltd Q3 FY2023 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2022-09-30
Dr Reddys Laboratories Ltd Q2 FY2023 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2022-06-30
Dr Reddys Laboratories Ltd Q1 FY2023 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2022-03-31
Dr Reddys Laboratories Ltd Q4 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2021-12-31
Dr Reddys Laboratories Ltd Q3 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2021-03-31
Dr Reddys Laboratories Ltd Q4 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2020-12-31
Dr Reddys Laboratories Ltd Q3 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2020-06-30
Dr Reddys Laboratories Ltd Q1 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q3
2019-12-31
Dr Reddys Laboratories Ltd Q3 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2019-09-30
Dr Reddys Laboratories Ltd Q2 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Showing 1–20 of 20 earnings calls
Key facts
CIK
1135951
CUSIP
256135203
13F (30d)
80 filings
59 filers
Visit website
Investor relations